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Abstract
Background: The physiological function of the cellular prion protein (PrPC) remains unknown.
However, PrPC has been reported to possess a cytoprotective activity that prevents death of
neurons and other cells after a toxic stimulus. To explore this effect further, we attempted to
reproduce several of the assays in which a protective activity of PrP had been previously
demonstrated in mammalian cells.
Results: In the first set of experiments, we found that PrP over-expression had a minimal effect
on the death of MCF-7 breast carcinoma cells treated with TNF-α and Prn-p0/0 immortalized
hippocampal neurons (HpL3-4 cells) subjected to serum deprivation. In the second set of assays,
we observed only a small difference in viability between cerebellar granule neurons cultured from
PrP-null and control mice in response to activation of endogenous or exogenous Bax.
Conclusion: Taken together, our results suggest either that cytoprotection is not a physiologically
relevant activity of PrPC, or that PrPC-dependent protective pathways operative in vivo are not
adequately modeled by these cell culture systems. We suggest that cell systems capable of
mimicking the neurotoxic effects produced in transgenic mice by N-terminally deleted forms of PrP
or Doppel may represent more useful tools for analyzing the cytoprotective function of PrPC.
Background
Prion diseases, also known as transmissible spongiform
encephalopathies, are fatal neurodegenerative disorders
that occur when the normal, cellular prion protein (PrPC)
is converted into a conformationally altered isoform
(PrPSc) that is self-propagating and infectious [1,2]. While
the properties of PrPSc and its role in the disease process
have been extensively characterized, the normal physio-
logical function of PrPC has yet to be resolved. Mice genet-
ically lacking PrPC exhibit no gross anatomical or
developmental abnormalities, and have been largely
uninformative for deducing a physiological function of
PrPC [3-5]. Several potential functions have been pro-
posed for PrPC, including protection from apoptosis and
oxidative stress, maintenance of synaptic integrity, regula-
tion of copper metabolism, cell signaling, and cell adhe-
sion (reviewed in [6]). Whatever the physiological
function of PrPC, it has become increasingly clear that
expression of PrPC is necessary to mediate the toxicity
induced by PrPSc [7-9]. Therefore, determining the normal
function of PrPC will likely provide important insight into
the neurotoxic mechanisms underlying prion diseases.
The most compelling evidence for a functional activity of
PrPC comes from studies in mice expressing either certain
N-terminally deleted forms of PrP or the PrP paralog,
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Doppel (Dpl). Several different deletions that encompass
a highly conserved sequence of 21 amino acids in the cen-
tral region of PrP all cause a spontaneous neurodegenera-
tive illness when expressed in the brains of transgenic
mice [10-12]. A neurodegenerative phenotype is also
observed in mice in which Dpl, a PrP paralog that is nor-
mally expressed in testes and structurally resembles the C-
terminal globular domain of PrP, is ectopically expressed
in the brain [13-16]. Strikingly, neurodegeneration
induced by deleted PrP molecules and Dpl is reversed by
co-expression of wild-type PrP [10-12,17]. These results
have been interpreted to mean that deleted PrP and Dpl
activate a common neurotoxic pathway, and that this
pathway is suppressed by the presence of wild-type PrP.
The dramatic rescuing effect by wild-type PrP in these
transgenic mice raises the possibility that PrPC possesses a
generalized neuroprotective activity that could counteract
the effects of other toxic stimuli [6,18]. One kind of evi-
dence consistent with this idea derives from studies of cul-
tured neurons or mice that lack PrP expression. For
example, it has been reported that neurons cultured from
Prn-p0/0 mice are more susceptible than wild-type neurons
to several kinds of oxidative stress including exposure to
xanthine oxidase, hydrogen peroxide, and copper ions
[19]. There is also evidence that PrPC may play a protective
role in vivo during focal cerebral ischemia or traumatic
brain injury. PrPC expression levels increase after these
kinds of injury and lesion size is larger in Prn-p0/0 com-
pared to wild-type mice [20,21]. Retinal photoreceptors
from Prn-p0/0 mice have also been reported to be more sus-
ceptible to light-induced apoptosis [22].
Several in vitro systems have also been described in which
increased PrP expression has been found to exert a protec-
tive effect against apoptotic insults [23]. In one such sys-
tem, human fetal neurons in culture were induced to
undergo apoptosis by microinjection of a plasmid encod-
ing the pro-apoptotic protein, Bax. Co-injection of a PrP-
encoding cDNA efficiently prevented Bax-induced neuro-
nal death [24]. This protective effect has been attributed to
the presence of a cytosolic form of PrP, which is thought
to inhibit conformational activation of Bax [25-27]. In a
second example, serum deprivation of two kinds of
immortalized hippocampal cell lines (HpL and NpL)
derived from Prn-p0/0 mice triggered an apoptotic response
that was rescued by transfection with a PrP-encoding plas-
mid [28-30]. Over-expression of PrPC has also been
reported to render MCF-7 breast carcinoma cells resistant
to apoptosis induced by TNF-α, TRAIL, and Bax
[25,27,31,32]. PrP expression also correlated with
increased resistance of SGC7901 gastric carcinoma cell
lines to several chemotherapeutic agents [33]. Finally,
work in our own laboratory has shown that expression of
mammalian PrP markedly protects S. cerevisiae from Bax-
induced cell death [34]. Although these studies utilize a
variety of cell types and a range of different stimuli to
induce cell death, it is possible that the protective activity
of PrP observed in each case reflects a common, underly-
ing molecular mechanism. However, the nature of this
mechanism remains unknown.
In this study, we have re-examined the cytoprotective
activity of PrP in three different mammalian cell systems
similar to those that have been previously published. We
first attempted to reproduce the rescue effect of PrP in
TNF-α-treated MCF-7 cells and serum-deprived HpL cells.
To examine the protective activity of PrP in primary neu-
rons, we assessed the ability of PrP to inhibit apoptosis of
cerebellar granule neurons induced by expression of exog-
enous Bax and by activation of endogenous Bax following
potassium and serum withdrawal [35]. While our results
demonstrate a weak cytoprotective effect by PrP in each of
these systems, the degree of protection was considerably
less than in previously published studies. The modest
cytoprotective effects observed here lead us to consider
whether PrP possesses any physiologically relevant neuro-
protective activity, and if so, whether the toxic stimuli
used did not effectively activate the relevant PrP-depend-
ent pathways. This work has important implications for
the design of experimental strategies aimed at uncovering
the mechanisms of PrPC cytoprotection.
Results
Expression of PrP in MCF-7 cells weakly suppresses death 
induced by TNF-α
To test the observation that PrPC rescues MCF-7 human
breast carcinoma cells from TNF-α-mediated cell death
[31], we first determined the sensitivity of MCF-7 cells to
TNF-α treatment using two different assays: MTT dye
reduction, and flow cytometry after propidium iodide
staining to measure the proportion of cells with sub-2n
DNA content. Treatment of untransfected MCF-7 cells
with 100 ng/ml TNF-α diminished cell viability over time,
with the MTT signal reduced to ~30% after 72 hrs (Figure
1A). A similar time course of cell death was observed by
flow cytometry, with the proportion of cells containing
sub-2n DNA reaching ~65% by 72 hrs (Figure 1B). These
data confirm the susceptibility of MCF-7 cells to cell death
induced by treatment with TNF-α in the absence of exog-
enous PrP expression.
To test the rescuing effect of PrP, we generated pools of
MCF-7 cells that were transfected either with an empty
vector, or with vector encoding human PrP. We analyzed
three independent pools of vector-transfected cells which
express low levels of endogenous PrP, and six pools of
cells expressing high levels of transfected PrP (~20–25-
fold over endogenous) (Figure 2A). Each pool was treated
with 100 ng/ml TNF-α for 43 hrs, and then assayed by
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MTT and flow cytometry. We observed that the PrP-
expressing pools displayed a small, but statistically greater
viability compared to vector-transfected pools based on
the MTT assay (Figure 2B): 47% (PrP) vs. 38% (vector) (p
= 0.0042). Less cell death was also observed in PrP-
expressing cells than in vector controls, as measured by
the proportion of cells with sub-2n DNA content (Figure
2C): 35% (PrP) vs. 42% (vector).
PrP weakly suppresses death of immortalized 
hippocampal neurons following serum deprivation
PrP has also been reported to exert a protective activity in
immortalized hippocampal cell lines derived from Prn-p0/
0 mice (HpL cells) subjected to serum deprivation [29].
We obtained two independently generated HpL cell lines
(HpL3-2 and HpL3-4) and tested their susceptibility to
serum withdrawal. Both lines underwent cell death over a
comparable time course, with ~30% of the cells remaining
viable after 72 hrs (Figure 3A).
We then generated stably transfected lines of HpL3-4 cells
expressing wild-type mouse PrP, and tested their suscepti-
bility to cell death following serum deprivation. We ana-
lyzed four independent lines that expressed differing
levels of PrP, based on immunofluorescence staining (Fig-
ure 3B). PrP-expressing and vector-transfected lines were
deprived of serum for 96 hrs, and cell death was measured
by flow cytometry (Figure 3C). Data was normalized rela-
tive to untreated controls. We observed a modest rescuing
effect that was correlated with the level of PrP expression
level. Two lines expressing the highest levels of PrP dis-
played a reduced level of cell death that was statistically
significant relative to a vector control (PrP4-1, p = 0.0068;
PrP4-2, p = 0.0022). All PrP-expressing clones showed less
cell death than a vector control clone (V1-2), in which >
50% of the cells were dead by 96 hrs.
HpL cells do not express neuronal markers or Doppel
Since PrP did not dramatically rescue HpL cells from
serum deprivation as previously reported [29], we sought
to confirm the identity of these cells by analyzing their
expression of various neuronal and astrocytic markers
using immunofluorescence and quantitative RT-PCR
(Table 1). As previously reported [28,29], neither the
HpL3-2 nor HpL3-4 lines expressed appreciable levels of
GFAP. Surprisingly, however, we did not detect expression
of the neuronal markers NeuN, MAP2, or the 68 K neuro-
filament light-chain subunit (NF-L). These cells were pre-
viously reported to express NF-L [29]. Using the same
antibodies, we previously observed high levels of the neu-
ronal and astrocytic markers in brain (Table 1) [36].
HpL cells are derived from hippocampal neurons cultured
from Rikn Prn-p0/0 mice, in which an intergenic splicing
event caused Doppel to be ectopically expressed in brain
under control of the PrP promoter [37,38]. Unexpectedly,
quantitative RT-PCR and immunofluorescence analysis
failed to detect expression of Doppel in the HpL3-2 or
HpL3-4 cells (Table 1).
PrP does not significantly reduce death of cerebellar 
granule neurons (CGNs) induced by exogenous Bax
To test the hypothesis that PrP can inhibit Bax-induced
cell death, we transiently transfected a cDNA encoding
mouse Bax into CGNs cultured from either Prn-p+/+ or Prn-
p0/0 mice. A separate plasmid encoding EGFP was co-trans-
fected into the neurons as a marker of transfected cells. In
healthy neurons, EGFP fluorescence was distributed
evenly throughout the soma (Figure 4A, white arrow) and
continuously along the neurites (Figure 4A, inset). By
DAPI staining, the nucleus of healthy cells was relatively
large, and filled with multiple nucleoli (Figure 4B, white
Untransfected MCF-7 cells undergo cell death following treatment with recombinant TNF-αFigure 1
Untransfected MCF-7 cells undergo cell death follow-
ing treatment with recombinant TNF-α. (A) MCF-7 
cells were treated with 100 ng/ml TNF-α, and cell viability 
was assessed using the MTT assay. Absorbance values are 
expressed as a percentage of those in non-treated control 
samples at each timepoint. Error bars are derived from tripli-
cate wells of one representative experiment. (B) Flow 
cytometry analysis of untreated or TNF-α-treated MCF-7 
cells. Cells were trypsinized, fixed in ethanol, and incubated 
with propidium iodide prior to analysis by flow cytometry. 
10,000 cells were counted for each condition. Data are 
expressed as the percentage of cells containing sub-2n DNA 
content in one representative experiment.
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arrow). Cell death induced by Bax resulted in characteris-
tic morphological changes that were easily visualized by
EGFP and DAPI fluorescence. Dying granule cells dis-
played a soma that was shrunken (Figure 4C, yellow
arrow), as well as coalescence of EGFP into large, uncon-
nected aggregates or beads along the neuritic process,
indicative of neuritic degeneration (Figure 4C, inset). Co-
staining with DAPI also revealed pyknotic nuclei (Figure
4D, yellow arrow).
Eight hours after transfection of Prn-p0/0 cultures with the
Bax plasmid, 39% of EGFP-positive neurons were degen-
erating based on morphological criteria (Figure 4E). Cul-
tures from Prn-p+/+ mice displayed a reduced percentage of
apoptotic neurons (23%), although this difference was
not statistically significant (p = 0.3038). By 16 hrs after
transfection, Prn-p0/0 cultures contained more degenerat-
ing CGNs than Prn-p+/+ cultures, a difference that
approached but did not reach statistical significance (21%
vs. 7%, respectively; p = 0.0665). Cultures derived from
either Prn-p0/0 or Prn-p+/+ mice transfected with empty vec-
tor (without Bax) contained < 2% apoptotic CGNs.
CGNs expressing PrP are slightly more resistant to cell 
death induced by potassium/serum deprivation
To determine whether PrP protects neurons from death
due to activation of endogenous Bax, CGNs from wild-
type and Prn-p0/0 mice were transferred to medium con-
taining reduced potassium and no serum. To improve via-
bility, CGNs are routinely cultured in the presence of
serum under depolarizing conditions with elevated potas-
sium (25 mM). Reducing potassium to 5 mM and remov-
ing serum causes the cells to undergo Bax-dependent
apoptosis [39,40]. Using calcein AM fluorescence to
detect viable neurons, we observed that incubation in
low-potassium medium without serum (K5-S) gradually
Expression of human PrP mildly suppresses TNF-α-mediated death of MCF-7 breast carcinoma cellsFigure 2
Expression of human PrP mildly suppresses TNF-α-mediated death of MCF-7 breast carcinoma cells. (A) PrP 
expression was assessed by western blotting of three pools of vector-transfected MCF-7 cells (lanes 1–3) and six pools of 
MCF-7 cells transfected with a human PrP plasmid (lanes 4–9). (B) Pools of MCF-7 cells were treated with 100 ng/ml of recom-
binant TNF-α for 43 h. Cell viability was determined by the MTT assay. Absorbance values are expressed as a percentage of 
those in non-treated control samples. Data represent the mean ± SEM from 3 vector-transfected pools and 6 PrP-transfected 
pools. *p = 0.0042, human PrP vs. vector. (C) Pools of MCF-7 cells were treated with 100 ng/ml of recombinant TNF-α for 43 
h. Cell viability was determined by flow cytometry after staining with propidium iodide. 10,000 cells were counted for each 
condition, and data are expressed as the percentage of cells containing sub-2n DNA. Data are derived from 4 MCF-7(hPrP) 
pools (mean ± SEM) and one vector control pool.
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reduced the viability of Prn-p+/+ CGNs to 56% of the value
for cells maintained in control medium (K25+S) after 48
hrs (Figure 5, open circles). CGNs cultured from Prn-p0/0
mice consistently followed a slightly faster reduction in
viability, with 45% of the neurons surviving after 48 hrs
(Figure 5, open triangles). The difference in viability
between the two types of neurons was statistically signifi-
cant at 24 and 48 hrs (p = 0.0358 and 0.0302, respec-
tively). These data demonstrate that endogenous PrP
expression slightly reduces, but does not prevent, Bax-
dependent cell death of CGNs induced by lowering extra-
cellular potassium and removing serum.
Stable expression of PrP weakly suppresses death of immortalized Prn-p0/0 hippocampal neurons after serum deprivationFigure 3
Stable expression of PrP weakly suppresses death of immortalized Prn-p0/0 hippocampal neurons after serum 
deprivation. (A) Two untransfected lines of Prn-p0/0 HpL cells (3–2 and 3–4) were subjected to 72 hours of serum depriva-
tion. Cell viability was determined by MTT assay. Absorbance values are expressed as a percentage of those in non-treated 
control samples at each timepoint. Data are from one representative experiment. (B) Immunofluorescence analysis of mouse 
PrP expression in two PrP-expressing lines of HpL3-4 cells (4-1 and 4-2), and one vector-transfected line. PrP was detected by 
staining with the PrP antibody (green). Cells were counterstained with giantin, a marker for the Golgi apparatus (red). PrP 
expression was detectable on the cell surface and in the Golgi apparatus. Bar = 50 μm. (C) HpL3-4 cell lines were subjected to 
96 hours of serum deprivation, after which cell viability was determined by flow cytometry after propidium iodide staining. 
10,000 cells were counted for each condition. Data are expressed as the percentage of cells containing sub-2n DNA content, 
and represent the mean ± SEM from three independent experiments. *p < 0.01, PrP vs. vector. Relative PrP expression for 
each cell line is indicated below each set of bars by the number of "+" symbols.
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Discussion
In this study, we tested the ability of PrP to protect cul-
tured cells from several kinds of cytotoxic insults using
assays similar to those that have previously been pub-
lished by other investigators. We examined the effect of
PrP expression on the viability of MCF-7 breast carcinoma
cells treated with TNF-α, HpL3-4 immortalized hippoc-
ampal neurons deprived of serum, and cultured cerebellar
granule neurons induced to undergo two kinds of Bax-
dependent apoptosis. In contrast to previously published
reports, we failed to detect a robust protective effect of PrP
in any of these assays. These results have led us to critically
reevaluate the function of PrP as a cytoprotective mole-
cule.
The protective activity of PrP in MCF-7 and HpL3-4 cells is 
more modest than previously described
In a DNA microarray analysis, Diarra-Mehrpour et al. [31]
found that PrP expression was up-regulated 17-fold in a
sub-line of MCF-7 cells that was resistant to TNF-α-
induced apoptosis. These investigators then showed that
adenovirally-mediated over-expression of PrP in the
parental TNF-α-sensitive MCF-7 cell line conferred resist-
ance to TNF-α, an effect that correlated with reduced cyto-
Table 1: Analysis of marker proteins in HpL3-2 and HpL3-4 cells by immunofluorescence and quantitative RT-PCR.
SAMPLE IMMUNOFLUORESCENCE qRT-PCR
NeuN MAP2 GFAP NF-L GFAP Doppel
HpL3-2 - - - - - -
HpL3-4 - - - - - -
Brain + * + * + * + + N/A
Testes N/A N/A N/A N/A N/A +
* Immunofluorescence detection of NeuN, MAP2, and GFAP in brain sections was performed previously [36].
PrP does not significantly reduce death of cerebellar granule neurons induced by exogenous BaxFigure 4
PrP does not significantly reduce death of cerebellar granule neurons induced by exogenous Bax. (A-D) Repre-
sentative fluorescence images of cerebellar granule neurons from Prn-p0/0 mice transfected with plasmids encoding EGFP and 
mouse Bax. Four days after transfection, cultures were stained with DAPI, and EGFP-positive neurons were scored as healthy 
(A, B) or apoptotic (C, D) based on morphological criteria. These criteria included the distribution of EGFP in the soma and 
neurites, and the appearance of DAPI staining in the nucleus (see text). (E) CGNs cultured from Prn-p+/+ or Prn-p0/0 pups were 
transfected with plasmids encoding Bax and EGFP. Cultures were fixed and stained with DAPI either 8 or 16 hours after trans-
fection, and scored for apoptotic morphology. Data represent the mean ± SEM from at least three independent experiments. 
The difference between Prn-p0/0 and Prn-p+/+ neurons did not reach statistical significance at either time point (p > 0.05).
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chrome c release from mitochondria. In their experiment,
~80% of PrP-expressing cells remained viable after TNF-α
treatment compared with ~30% for untransduced cells. In
our hands, in contrast, over-expression of PrP in MCF-7
cells by a similar amount had a much more modest effect,
increasing viability after TNF-α treatment from 38% to
47% (Figure 2B).
Although a number of published studies have utilized
HpL3-4 cells to demonstrate a neuroprotective activity of
PrP [28-30,37,41-46], only two report quantitative data
concerning the ability of PrP to rescue these cells from
serum deprivation [41,42]. In one of these studies [42],
stable expression of PrP in HpL3-4 cells was reported to
reduce cell death by 80% relative to vector controls based
on LDH assays of cell death. However, the LDH data were
normalized to the values for vector-transfected cells after
24 hours of serum deprivation, so it is not possible to
gauge of the absolute amount of cell death occurring in
these experiments. In the second study [41], serum depri-
vation reduced the viability of vector-transfected cells by
only a modest amount (to 75% of the value for untreated
cells) and PrP expression restored viability to nearly 100%
after 24 hours. In our experiments, stable expression of
PrP in several independent HpL3-4 cell lines produced
only a small reduction in cell death, amounting to < 20%,
even in lines expressing the highest levels of PrP (Figure
3C).
It is unclear what factors account for the discrepancies
between our results and those reported in previous stud-
ies. In the case of MCF-7 cells, one possible reason may be
a difference in the methods used to introduce exogenous
PrP: stable transfection in our experiments vs. adenoviral
transduction in the study of Diarra-Mehrpour et al. [31].
However, both methods achieved similar levels of over-
expression (~25-fold). Alternatively, genetic variation
between different lines of MCF-7 cells may play a role.
Susceptibility of MCF-7 cells to TNF-α treatment is greatly
influenced by genetic factors, leading to cell line variants
with differing sensitivities to TNF-α-induced apoptosis
[47,48]. Signaling molecules influencing the response to
TNF-α also differ between variants of MCF-7 cells, includ-
ing PKCε, JNK, p53, and NF-κB [49-53]. The diversity of
factors that affect TNF-α-mediated cell death in MCF-7
cells suggest that the previously described protective effect
by PrP may be specific for a particular strain variant and
may not be generally reproducible in other cell types.
Similar genetic changes may have occurred in HpL3-4
cells, since we did not detect expression of NF-L or Doppel
by quantitative RT-PCR (Table 1). The absence of NF-L
expression in the HpL3-4 and HpL3-2 cells suggests that
they may have lost their neuronally differentiated charac-
teristics, which may be required for the rescue activity.
PrP does not strongly rescue cultured neurons from Bax-
dependent apoptosis
We have proposed several possible mechanisms to
explain how PrP could exert a protective effect against Bax-
mediated cytotoxic insults [6]. PrP may act on death
receptors at the cell surface, it may influence the activity of
pro- and anti-apoptotic molecules by physical interaction
or via signal transduction pathways, or it could work
within intracellular organelles to influence cell death
pathways. To test whether PrP could modulate Bax-
dependent pathways, we utilized cultured CGNs in an
attempt to recapitulate the dramatic rescue activity that
was described in analogous experiments on human pri-
mary neurons [24]. We chose to utilize CGNs for two rea-
sons. First, CGNs undergo Bax-dependent apoptosis in
response to reduced extracellular potassium and serum
deprivation, and this process has been analyzed exten-
sively to gain insight into the mechanisms of programmed
cell death [40,54]. Second, CGNs have been used by oth-
ers to demonstrate a neuroprotective activity of PrP
against Dpl [55,56].
In contrast to the previous study [24], we failed to observe
a robust protective effect of PrP against apoptosis induced
either by ectopic expression of Bax or by activation of
endogenous Bax via potassium depletion and serum dep-
rivation. In these experiments, the presence of PrP
enhanced cell viability by at most 15%. The reasons for
CGNs expressing PrP are slightly more resistant to cell death induced by potassium/serum deprivationFig re 5
CGNs expressing PrP are slightly more resistant to 
cell death induced by potassium/serum deprivation. 
CGNs cultured from Prn-p0/0 and Prn-p+/+ mice were cultured 
in K25+S medium for 7 days, after which they were trans-
ferred to K5-S medium for the designated times. Cell viability 
was assessed by measurement of calcein fluorescence on a 
microplate fluorimeter. Fluorescence values in K5-S medium 
are expressed as a percentage of those in K25+5 medium at 
each time point. Data represent the mean ± SEM for at least 
two independent experiments. * p < 0.05, Prn-p+/+ vs. Prn-p0/0.
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this discrepancy are unclear, but differences in neuronal
populations (cortical versus cerebellar), species (human
versus mouse), or PrP expression level may play a role.
With regard to the last point, Bounhar et al. utilized
microinjection of a cDNA-encoding plasmid in order to
boost PrP expression in neurons that presumably already
contained endogenous PrP, although no data were pre-
sented on the degree of over-expression achieved [24]. In
contrast, we compared neurons completely lacking PrP to
those containing normal endogenous levels. It is possible
that Bax rescue activity is only observed with supraphysi-
ological expression levels of PrP.
The role of Bax in the physiological activity of PrPC
remains uncertain, with some studies suggesting a func-
tional connection between the two proteins and others
arguing against it. Our own studies [34] as well as those of
others [57] demonstrate that S. cerevisiae yeast cells
expressing mammalian PrP are protected from Bax-
induced cell death. In addition, PrP expression was shown
to reduce cell death in MCF-7 cells by inhibiting a pro-
apoptotic conformational change in Bax [25]. Deletion of
the Bax gene rescues neuronal loss in Tg(PG14) mice
expressing a disease-associated mutant PrP with impaired
neuroprotective activity [58,59] but does not prevent neu-
ronal death in transgenic mice expressing PrPΔ105-125 or
PrPΔ32-134 [60]. Bax deletion has no effect on the disease
course in scrapie-infected mice [61,62]. Since PrP is
largely present on the cell surface and Bax is localized to
the cytosol, interaction between the two proteins, if it
occurs, must either be indirect or else involve rare
cytosolic forms of PrP [26,27]. Relevant to this issue, there
is evidence that cytosolic PrP physically associates with
the Bax antagonist, Bcl-2 [63], but not with Bax itself [25].
Cell culture models to investigate the cytoprotective 
activity of PrP
In a number of cell types, expression of PrP seems to exert
a protective effect against several different toxic insults
[6,23]. Although we failed to observe a robust protective
activity when we re-examined three of the published sys-
tems, we did note that the presence of PrP was associated
with a small improvement (< 20%) in cell viability in
some of our experiments. Whether these effects observed
in cell culture experiments reflect a physiologically rele-
vant activity of PrPC remains to be determined. It is possi-
ble that they represent in vitro artifacts due to PrP over-
expression or other factors. Alternatively, PrPC may pos-
sess a cytoprotective activity in vivo that is not easily repro-
duced in cell culture models. This might be the case if the
cellular stresses applied experimentally do not adequately
mimic those operative in brain tissue, or because cultured
cells lack some of the relevant PrP-dependent death path-
ways.
At present, the most compelling evidence for a role of PrP
in cytoprotective and cytotoxic phenomena comes from
mice expressing Dpl or PrP forms harboring deletions that
span residues 105–125 [10-12,15]. These molecules pro-
duce a dramatic neurodegenerative phenotype that is
dose-dependently suppressed by co-expression of wild-
type PrP. Therefore, it would seem that cell culture sys-
tems capable of reproducing this phenomenon would be
the most useful tools for investigating the toxic and pro-
tective activities of PrPC. Several reports have appeared in
which expression of Dpl or deleted PrP forms in cultured
cells impairs viability, with co-expression of wild-type PrP
suppressing this effect [37,55,56,64]. Further develop-
ment of these and other cell models will greatly aid in
deciphering the physiological function of PrPC, and how
it might be subverted during the disease process.
Conclusion
In this study, we investigated the cytoprotective activity of
PrPC in several mammalian cell culture systems. In each
system tested, expression of wild-type PrP elicited a mod-
est protective effect, although less than in previously pub-
lished studies. We conclude that the cytoprotective
activity of PrPC observed in vivo is not easily recapitulated
in vitro. Either the cellular stresses employed do not
engage a PrPC-dependent pathway, or cytoprotection is
not a physiologically relevant activity of PrPC.
Methods
Cell lines
MCF-7 and HpL cells were cultured in DMEM supple-
mented with 10% FCS, 2 mM glutamine, and penicillin/
streptomycin, and were maintained in a humidified incu-
bator at 37°C in 5% CO2.
MCF-7 cells were transfected with a pcDNA3 plasmid
encoding wild-type human PrP using Lipofectamine 2000
(Invitrogen, Carlsbad, CA) according to the manufac-
turer's protocol. Forty-eight hours later, cells were split
into 700 μg/ml G418 (Tissue Culture Support Center,
Washington University in St. Louis) for two weeks. Cells
were harvested as pools and maintained in 300 μg/ml
G418. PrP expression was detected by Western blotting of
cell lysates using the monoclonal anti-PrP antibody, 3F4
(1:1000) [65].
HpL3-4 cells were transfected with wild-type mouse PrP
cDNA contained in a pcDNA3.1(+)/hygro vector (Invitro-
gen). After transfection with Lipofectamine 2000, cells
were selected in media containing 200 μg/ml hygromycin
B (Invitrogen). Upon selection of stable lines, cells were
maintained in 100 μg/ml hygromycin B.
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PrP expression was assessed by Western blotting using the
monoclonal 3F4 antibody (MCF-7 cells), or by immun-
ofluorescence staining (HpL cells, see below).
Immunofluorescence staining of HpL cells
HpL cells were fixed with 4% paraformaldehyde, permea-
bilized with 0.5% Triton-X100 in PBS, and blocked in 5%
goat serum in PBS. Cells were incubated with the mono-
clonal anti-PrP antibody 8H4 [66], and co-stained with
antibodies to the Golgi marker, giantin (1:1000; Covance,
Berkley, CA). In some experiments, cells were stained with
antibodies to GFAP (1:1000; Dako, Carpinteria, CA),
MAP-2 (1:1000; Sigma, St. Louis, MO) and NeuN
(1:1000; Chemicon, Temecula, CA). After incubation
with primary antibodies, cells were treated with Alexa
Fluor secondary antibodies (Alexa-488 goat anti-mouse
IgG and Alexa-594 goat anti-rabbit IgG) prior to imaging
using a Nikon OptiPhot-2 microscope and MetaMorph
imaging software.
Measurement of death and viability of MCF-7 and HpL 
cells
Stably transfected pools of MCF-7 cells expressing human
PrP were treated with 100 ng/ml recombinant TNF-α
(PeproTech, Rocky Hill, NJ) in growth medium for 43
hours. Stimulation of cell death by serum deprivation in
HpL3-2 and HpL3-4 cells was performed as previously
described [29].
For MTT viability assays, medium was replaced with 0.32
mg/ml MTT (3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-
2H-tetrazolium bromide; Sigma, St. Louis, MO) in Locke's
buffer for 30–60 minutes. Cells were solubilized with
DMSO and the absorbance was read at 575 nm in a micro-
plate reader (Bio-Tek, Winooski, VT). Experimental values
were expressed as a percentage of the absorbance values in
non-treated control samples.
For flow cytometry analysis, cells were washed once with
PBS prior to trypsinization and fixation in 70% cold etha-
nol. After fixation, cells were washed in PBS/1% BSA, pel-
leted, and resuspended in propidium iodide (PI) working
solution containing 30 μg/ml PI (Sigma) and 0.25 mg/ml
RNAse A (Qiagen, Valencia, CA) in PBS/1% BSA. The vol-
ume of PI working solution was normalized for cell
number. Flow cytometry was performed on a FACSCali-
bur flow cytometer (BD Biosciences, San Jose, CA), and
the data was analyzed using CELLQUEST analysis soft-
ware (BD Biosciences).
Quantitative RT-PCR analysis
mRNA was purified from HpL3-4 and HpL3-2 cells and
wild-type mouse brain and testes using the RNAwiz rea-
gent (Ambion, Austin, TX). cDNA was generated, and
expression of GFAP, NF-L, and Doppel was analyzed by
quantitative RT-PCR using an ABI-PRISM 7000 Sequence
Detection System (Applied Biosystems, Foster City, CA).
Primers specific for GFAP, NF-L, and Doppel were
designed using the Primer Express program. Primer pairs
used were as follows: GFAP forward (CTGGAGGTGGA-
GAGGGACAA), GFAP reverse (CAGCCTCAGGTTGGTT-
TCATCT), NF-L forward (CCGGCCGCCACCAT), NF-L
reverse (CCACATAGCGCCGCTTGTA), Dpl forward
(GCTGGTGGGCAAAGGTAGAC), Dpl reverse
(TGAAACGCTACACGTTGTACTTTCA). Data were nor-
malized to GAPDH expression using forward (GGT-
GGACCTCATGGCCTACA) and reverse
(AGGGCCTCTCTCTTGCTCAGT) primers.
Cerebellar granule neuron (CGN) cultures
CGNs were cultured from wild-type C57BL/6J × CBA/J
mice or from Prn-p0/0 mice [3]. Cultures were prepared
from 5-day-old mouse pups as described previously [35].
Neurons were suspended in K25+S medium (Basal Media
Eagle with Earle's salts without glutamine, 10% dialyzed
FCS, 2 mM glutamine, 25 mM KCl, and 0.02 mg/ml gen-
tamicin) and plated in chamber slides coated with poly-
D-lysine at a density of 560,000 cells/cm2. Two hours after
plating, the medium was changed to K25 medium (no
serum) supplemented with B27 (Invitrogen). Four days
after plating, conditioned medium was removed and
replaced with fresh K25+B27 medium. CGNs were co-
transfected with 1 μg DNA (1:1 ratio of mouse Bax and
pEGFP-N1 (Clontech, Mountain View, CA)) using Lipo-
fectamine 2000. Mouse Bax cDNA was obtained from
Open Biosystems (#MMM1013-64655; Huntsville, AL),
PCR amplified, and cloned into the pcDNA3.1(+)/hygro
plasmid (Invitrogen). After 2 hours, the neurons were
returned to conditioned K25+B27 medium.
Transfected CGNs were fixed in 4% paraformaldehyde/
5% sucrose in PBS for 10 minutes at room temperature.
Nuclei were stained with DAPI for 10 minutes. Death of
EGFP-positive neurons was determined morphologically
based on chromatin condensation, degeneration of neur-
ites, and cell body shrinkage. At least 100 neurons were
individually scored for each experiment. Cells were
imaged using a Nikon OptiPhot-2 microscope and Meta-
Morph imaging software.
CGNs were subjected to reduced extracellular potassium
(5 mM) and serum deprivation as previously described
[35]. Following this manipulation, neurons were washed
twice with Locke's buffer and incubated for 10 minutes in
5 μM calcein AM (Invitrogen) in Locke's buffer at 37°C.
CGNs were washed once with Locke's buffer and lysed in
PBS/0.1% Triton-X100 followed by quantitation of the
fluorescence signal on a microplate fluorimeter (Bio-Tek).
Experimental values were expressed as a percentage of the
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calcein AM fluorescence values in K25+S control samples
at each timepoint.
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